Trials / Recruiting
RecruitingNCT05188170
Niclosamide in Pediatric Patients With Relapsed and Refractory AML
Phase 1 Study of Niclosamide (ANA001) in Pediatric Patients With Relapsed and Refractory AML
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 2 Years – 25 Years
- Healthy volunteers
- Not accepted
Summary
Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Niclosamide | Niclosamide will be administered orally for 14 days. Each dose will be followed by backbone chemotherapy |
Timeline
- Start date
- 2022-11-21
- Primary completion
- 2026-07-01
- Completion
- 2026-12-01
- First posted
- 2022-01-12
- Last updated
- 2026-01-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05188170. Inclusion in this directory is not an endorsement.